A saliva-based RNA extraction-free workflow integrated with Cas13a for SARS-CoV-2 detection - Azmi, Iqbal; Faizan, Md Imam; Kumar, Rohit; Yadav, Siddharth Raj; Chaudhary, Nisha; Singh, Deepak Kumar; Butola, Ruchika; Ganotra, Aryan; Joshi, Gopal Datt; Jhingan, Gagan Deep; Iqbal, Jawed; Joshi, Mohan C; et al. (medRxiv, 2021)
A major bottleneck in scaling-up COVID-19 testing is the need for sophisticated instruments and well-trained healthcare professionals, which are already overwhelmed due to the pandemic. Moreover, the high-sensitive SARS-CoV-2 diagnostics are contingent on an RNA extraction step, which, in turn, is restricted by constraints in the supply chain. Here, we present CASSPIT (Cas13 Assisted Saliva-based & Smartphone Integrated Testing), which will allow direct use of saliva samples without the need for an extra RNA extraction step for SARS-CoV-2 detection. CASSPIT utilizes CRISPR-Cas13a based SARS-CoV-2 RNA detection, and lateral-flow assay (LFA) readout of the test results. The sample preparation workflow includes an optimized chemical treatment and heat inactivation method, which, when applied to COVID-19 clinical samples, showed a 97% positive agreement with the RNA extraction method. With CASSPIT, LFA based visual limit of detection (LoD) for a given SARS-CoV-2 RNA spiked into the saliva samples was ∼200 copies; image analysis-based quantification further improved the analytical sensitivity to ∼100 copies. Upon validation of clinical sensitivity on RNA extraction-free saliva samples (n=76), a 98% agreement between the lateral-flow readout and RT-qPCR data was found (Ct<35). To enable user-friendly test results with provision for data storage and online consultation, we subsequently integrated lateral-flow strips with a smartphone application. We believe CASSPIT will eliminate our reliance on RT-qPCR by providing comparable sensitivity and will be a step toward establishing nucleic acid-based point-of-care (POC) testing for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementDr. Ahmad received support from UGC as a start-up grant (F.4-5/2018 FRP Start-up grant). Dr. Mohan C Joshi received support from DBT/Wellcome Trust India Alliance with grant number IA/I/15/2/502086 the support. Dr Jawed Iqbal is supported by the Ramalingaswami Fellowship grant (BT/RLF/Re-entry/09/2015) from Department of Biotechnology (DBT), and Early Career Research Award grant (File No. ECR/ 2018/002114) from Science and Engineering Research Board (SERB), Department of Science & Technology, Government of India.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All necessary approvals have been obtained. Institutional ethical clearance was obtained from Safdarjung Hospital (IEC/VMMC/SJH/Project/2020-07/CC-06). The ethical clearance was also obtained from Jamia Millia Islamia (1/10/290/JMI/IEC/2020). Further, biosafety clearance was obtained from Jamia Millia Islamia (Ref.No.P1/12-21.12.2020). All the other relevant certificate and approvals have been archived. Patient consent was obtained for the collection of samples according to the ICMR GCP guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have followed all the necessary guidelines and archived the data related to this study. Supplementary data files are separately uploaded and original data files are documented as per the guidelines.CDCCenters for Disease ControlCOVID-19Coronavirus Disease 2019CRISPRClustered regularly Interspaced Short Palindromic RepeatsDETECTRDNA Endonuclease Targeted CRISPR Trans ReporterLAMPLoop-mediated isothermal amplificationLFALateral Flow AssayNACN-acetyl CysteinePCRPolymerase Chain ReactionPKProteinase KPOCPoint of CareRPARecombinase Polymerase AmplificationRT-LAMPReverse Transcription Recombinase Polymerase AmplificationRT-RPAReverse Transcription Loop-mediated isothermal amplificationRT-qPCRquantitative Reverse Transcription Polymerase Chain ReactionSARS-CoV-2Severe acute respiratory syndrome coronavirus 2SHERLOCKSpecific High-sensitivity Enzymatic Reporter un-LOCKingUS FDAUnited States Food and Drug Administration